First dose infusion reaction during anti-CD20 monoclonal antibody therapy in chronic lymphocytic leukemia associates with high IP-10 levels amid cytokine release syndrome

نویسندگان

چکیده

Abstract Intravenous (IV) anti-CD20 monoclonal antibody (mAb) therapy for chronic lymphocytic leukemia (CLL) patients often produces a first dose infusion reaction (FDIR) within the 2 h that requires careful monitoring to avoid serious complications and fatalities. To better understand FDIR, we studied blood samples collected from 37 treatment-naïve CLL in our clinical trial NCT03788291 undergoing IV treatment with 50 mg of mAb (rituximab). We analyzed four time points: baseline (prior infusion), 1 later (during at end (~2.5 h) 48 h. Infusion reactions (CTCAE (v5) grade ≥2 events) were managed by interrupting symptomatic treatment. 24 (65%) had FDIR all completed infusion. Patient characteristics including measures disease severity (Rai stage, IGHV mutation status, cytogenetic defects) did not correlate FDIR. High levels cells and/or CD20 their subsequent depletion resulting decreased serum complement are thought be risks However, measurements these parameters correlate. Induction cytokine release syndrome (CRS) may CRS was observed after The only significant associations higher IP-10, IL-6, IL-8, IP-10 most significant. Anti-CD20 activated cytotoxic effector cells, such as tissue-resident macrophages ingest via antibody-dependent cellular phagocytosis (ADCP), responsible events leading A mouse model vitro ADCP cell systems will useful further biology Supported funding Acerta/AstraZeneca, Cadregari Foundation, generous donation Elizabeth Aaron, NIH NCI grant number R21CA267040.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).

Eleven patients with relapsed fludarabine-resistant B-cell chronic lymphocytic leukemia (CLL) or leukemic variants of low-grade B-cell non-Hodgkin's lymphoma (NHL) were treated with the chimeric monoclonal anti-CD20 antibody rituximab (IDEC-C2B8). Peripheral lymphocyte counts at baseline varied from 0.2 to 294.3 x 10(9)/L. During the first rituximab infusion, patients with lymphocyte counts exc...

متن کامل

Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia.

Authors' disclosures of potential conflicts of interest are found at the end of this article. T he management of chronic lymphocytic leukemia (CLL), a malignant disorder of the lymphoid lineage (primarily B cells), has changed considerably in recent years. The development of agents targeting CD20, a trans-membrane calcium channel protein expressed on B cells, was a significant milestone in the ...

متن کامل

Citrobacter koseri cellulitis during anti-CD20 monoclonal antibody (ofatumumab) treatment for B-cell chronic lymphocytic leukaemia.

© 2010 The Authors. doi: 10.2340/00015555-0762 Journal Compilation © 2010 Acta Dermato-Venereologica. ISSN 0001-5555 Sir, Patients with leukaemia are at high risk of developing cutaneous or invasive opportunistic infections caused by unusual bacteria of low virulence or by fungi. Immunosuppression is related to the malignancy itself and/or the therapies. We report here an atypical presentation ...

متن کامل

Current status of monoclonal antibody therapy for chronic lymphocytic leukemia.

Despite many therapeutic options for chronic lymphocytic leukemia (CLL), the disease remains incurable. Since monoclonal antibodies and recombinant toxins that bind surface antigens expressed on the malignant lymphocytes have been developed, targeted therapy has become a vital option in treating CLL. Rituximab (Rituxan), a chimeric human-mouse anti-CD20 antibody, and alemtuzumab (Campath), a hu...

متن کامل

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)

Eleven patients with relapsed fludarabine-resistant B-cell chronic lymphocytic leukemia (CLL) or leukemic variants of low-grade B-cell non-Hodgkin’s lymphoma (NHL) were treated with the chimeric monoclonal anti-CD20 antibody rituximab (IDEC-C2B8). Peripheral lymphocyte counts at baseline varied from 0.2 to 294.3 3 109/L. During the first rituximab infusion, patients with lymphocyte counts excee...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Journal of Immunology

سال: 2023

ISSN: ['1550-6606', '0022-1767']

DOI: https://doi.org/10.4049/jimmunol.210.supp.146.10